Wei Li, Ph.D

Wei Li, Ph.D has a strong background in the biotechnology industry, with extensive experience in leadership roles and scientific advisory positions. Wei is currently serving as the Chief Scientific Officer at Cytovia Therapeutics. In addition, they are a Member of the Board of Directors at CytoLynx Therapeutics and Artus Therapeutics. Previously, they held the position of Chief Development Officer at OliX Pharmaceuticals, Inc. and also served on the Board of Directors at OliX US, Inc. Prior to these roles, Wei Li held executive positions at Boston Biomedical, where they played a crucial role in product development and management of cross-functional teams. Wei also worked as a Manager/Senior Investigator at ArQule. Wei'sacademic career includes positions as an Instructor and Research Fellow at Harvard Medical School. With a diverse range of experiences, Wei Li brings a deep understanding of biotechnology and pharmaceutical development to their current role.

Wei Li, Ph.D, has a solid educational background in the field of molecular virology. They earned their Bachelor's degree in Biochemistry from Sun Yat-sen University. Following this, Wei Li pursued a Doctor of Philosophy (PhD) in Molecular Virology at Georgia State University. Lastly, they completed a Postdoc at Harvard Medical School, specifically in the Department of Rheumatology, Immunology, and Allergy at Brigham & Women's Hospital.